Rafferty Asset Management, LLC Adaptimmune Therapeutics PLC Transaction History

Rafferty Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.33 - $2.28 $424,258 - $727,299	-318,991 Reduced 59.5%	217,123 $369,000
Q1 2022 May 13, 2022	SELL	$1.73 - $4.06 $122,222 - $286,834	-70,649 Reduced 11.64%	536,114 $1.1 Million
Q4 2021 Feb 10, 2022	SELL	$3.5 - $5.68 $469,532 - $761,983	-134,152 Reduced 18.11%	606,763 $2.28 Million
Q3 2021 Nov 10, 2021	SELL	$3.44 - $6.37 $269,008 - $498,134	-78,200 Reduced 9.55%	740,915 $3.83 Million
Q2 2021 Aug 10, 2021	SELL	$3.86 - $5.78 $823,129 - $1.23 Million	-213,246 Reduced 20.66%	819,115 $3.49 Million
Q1 2021 May 10, 2021	BUY	$4.9 - $6.83 $4.33 Million - $6.03 Million	883,301 Added 592.58%	1,032,361 $5.48 Million
Q4 2020 Feb 10, 2021	BUY	$4.0 - $9.2 $596,240 - $1.37 Million	149,060 New	149,060 $803,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $114M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.